Navigation Links
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
Date:8/6/2014

or 2014.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 24, 2014 (the "Form 10-K") and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in Europe and Canada, including successfully establishing a commercial operation in Europe and Canada an
'/>"/>

SOURCE InterMune, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Reports Second Quarter 2013 Financial Results And Business Highlights
4. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
5. InterMune Announces Presentations of New Research in IPF at ERS
6. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
7. InterMune to Divest Actimmune® (Interferon Gamma-1b)
8. Neurocrine Biosciences Reports Second Quarter 2014 Results
9. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
10. China Biologic Reports Financial Results for the Second Quarter of 2014
11. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... July 2, 2015 Legal-Bay LLC, The Lawsuit ... Joseph Goodwin in the Southern District of ... transvaginal mesh cases against Ethicon for a single trial ... cases for the 26 women include claims from the ... made my Johnson & Johnson,s Ethicon subsidiary. The cases ...
(Date:7/1/2015)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today announced ... the Cantor Fitzgerald Healthcare Conference in New York ... Cox , executive vice president and chief operating officer, will ... financial update on Wednesday, July 8, 2015 at 9:30 a.m. ... audio webcast of the presentation may be accessed from the ...
(Date:7/1/2015)... 2015 Research ... addition of the "2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in European Clinical Chemistry and ... Landscape is a new five-country strategic analysis ...
Breaking Medicine Technology:Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 22015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2
... USANA Health Sciences, Inc. (NYSE: ... are common in the average American diet and that dietary ...  However, USANA scientists and advising physicians caution that many important ... Dietary Guidelines for Americans, 2010 and that the ...
... 10, 2011 For the biopharmaceutical industry, the ... and difficulty - of interacting with patients to ... created both opportunities and challenges for approaching and ... To help marketing teams in the biopharmaceutical ...
Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2Innovations in Patient-Focused Initiatives to Improve Outcomes 2
(Date:7/2/2015)... ... , ... ActiveBunch.com recently launched as a social network created for people with ... lifestyle community, Active Bunch allows users to connect with like-minded fitness enthusiasts from around ... or group events. , The spokesperson for Active Bunch explained the idea behind ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... with care and precision. There is an art and science that goes into ... of successfully reshaping the facial features and lives of more than 2,500 satisfied ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from ... in Anniston for specialized disaster training. The team – composed of four clinicians ... California Hospital Association who attended the training, which is dedicated to preparing first ...
(Date:7/2/2015)... ... , ... After conducting a nationwide executive search led by healthcare ... Ariz., has hired Robert Trenschel, DO, as chief executive officer. A veteran physician executive ... his new duties at Yuma Regional Medical Center on July 13. , “Dr. Trenschel ...
(Date:7/2/2015)... ... 02, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it has made two key appointments at its ... Manager at Catalent’s Schorndorf facility, which provides large scale, complex oral solid manufacturing ...
Breaking Medicine News(10 mins):Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Catalent Makes Two Key European Appointments in Oral Dose Manufacturing 2
... from product design and development through ... ... a,leading product design and development company, announced today that it has,received ... Services, Division of Food, Drug and Radiation Safety to,manufacture class I ...
... is the first Southern-style canned product ... by the American Heart Association, COLUMBUS, Ohio, Jan. ... lower sodium, low fat and meatless, were the first,product ... maintaining a savory,taste. Now, heart-healthy Sensibly Seasoned products also ...
... HARRISBURG, Pa., Jan. 9 Consumption of,sugary beverages can ... know that,some soft drinks contain as much as 11 ... also contain phosphoric and citric acids? Prolonged,exposure to these ... from the,tooth surface., According to Dr. Bruce Terry, ...
... Georgia Locations, ATLANTA, Jan. 9 Georgia Cancer Specialists ... -- will team,up with WSB-TV for the sixth annual "Totes ... GCS offices across Georgia on Friday, January 18,2008, from 10 ... or nearly new suitcases to foster children,in Georgia, many of ...
... say , , WEDNESDAY, Jan. 9 (HealthDay News) -- Researchers ... acid (RNA) molecules that seem to control whether or ... , These "microRNAs" essentially serve as brakes on the ... the disease to spread freely. When they are restored, ...
... WEDNESDAY, Jan. 9 (HealthDay News) -- Two new studies ... wisdom of treating with corticosteroids, intensive insulin therapy or ... , The first study compared the use of hydrocortisone ... found no improvement in survival rates. , The second ...
Cached Medicine News:Health News:Hiemstra Approved to Manufacture Medical Devices in New CER 2Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Keep a Watchful Eye on Sugary Beverage Consumption 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 2Health News:Georgia Cancer Specialists to Sponsor Sixth Annual 'Totes 2 Tots' Suitcase Drive for Foster Children 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 2Health News:Tiny RNA Molecules Control Breast Cancer's Spread 3Health News:Tiny RNA Molecules Control Breast Cancer's Spread 4Health News:Standard Septic Shock Treatments Ineffective 2Health News:Standard Septic Shock Treatments Ineffective 3Health News:Standard Septic Shock Treatments Ineffective 4
... Opmi Vario/NC33 system microscope provides surgeons ... pathology. These microscopes are ideal for many ... compact. Ergonomically designed at every point of ... utilized in a surgical microscope allows intuitive ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
26 cm - 10 1/4, 140 mm - 5 1/2, bayonet-shaped, flexible, 90 angle, 4 mm...
Toothed pituitary rongeur....
Medicine Products: